The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar…
More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome — but approval isn’t a su…
It’s a busy day at the FDA today as panels meet to discuss two new drugs — one to help weight loss and the other to combat drug addiction — and decide whether to approve AstraZeneca’s new blood thinner medication.
…